VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

ISCT 2020 | Functional dosing of MSC-derived extracellular vesicles for the prevention of GvHD

Mauro Krampera • 31 May 2020
ISCT 2020
General GvHD
Treatment

Mauro Krampera, MD, PhD, of the University of Verona, Verona, Italy, outlines the use of mesenchymal stromal cell (MSC)-derived extracellular vesicles for the prevention of acute graft-versus-host disease (GvHD). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Mauro Krampera

12:40
Respiratory pathology of COVID-19 and potential for MSCs
Mauro Krampera • 31 May 2020

Related Videos

0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
2:34
Generating iSPC-derived MSCs with the Cymerus™ Platform
Ross Macdonald • 19 Apr 2022
The content of VJRegenMed is intended for healthcare professionals